Overview

Our ADP-A2M4CD8 SPEAR T-cell therapy is our first "next-generation" therapy and is directed to MAGE-A4, a member of the MAGE family of cancer testis antigens expressed in a number of solid tumor types. What differentiates this therapy from our ADP-A2M4 SPEAR T-cells is that these cells also express the CD8α co-receptor alongside the engineered TCR that targets MAGE-A4. Preclinical data indicate that co-expression of CD8α may broaden the immune response against solid tumors and increase antitumor activity by leveraging CD4+ cells into CD8+ killer or cytotoxic T‑cells while retaining their CD4+ helper function.

Our Trial

SURPASS (ADP-A2M4CD8)

This is a phase 1, open label, dose escalation clinical study to evaluate the safety and anti-tumor activity of next generation ADP-A2M4CD8 SPEAR T-cells in patients who are HLA-A*02 positive and have inoperable locally advanced urothelial cancer, melanoma, ovarian cancer, esophageal, esophagogastric junction (EGJ) cancer , gastric cancer, NSCLC, head and neck cancer, synovial sarcoma, or MRCLS expressing MAGE-A4.

View Clinical Trial

Publications

Please visit our Publications page for more information on ADP-A2M4CD8